168 related articles for article (PubMed ID: 29760556)
1. Rechallenge of oxaliplatin-containing regimens in the third- or later-line therapy for patients with heavily treated metastatic colorectal cancer.
Yang Q; Huang Y; Jiang Z; Wang H; Li W; Zhang B; Xie D
Onco Targets Ther; 2018; 11():2467-2473. PubMed ID: 29760556
[TBL] [Abstract][Full Text] [Related]
2. CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial.
Shi Y; Li J; Xu J; Sun Y; Wang L; Cheng Y; Liu W; Sun G; Chen Y; Bai L; Zhang Y; He X; Luo Y; Wang Z; Liu Y; Yao Q; Li Y; Qin S; Hu X; Bi F; Zheng R; Ouyang X
Cancer Commun (Lond); 2019 May; 39(1):28. PubMed ID: 31126331
[TBL] [Abstract][Full Text] [Related]
3. Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS.
Hong YS; Kim HJ; Park SJ; Kim KP; Lee JL; Park JH; Kim JH; Lim SB; Yu CS; Kim JC; Baek JY; Kim SY; Kim TW
Cancer Sci; 2013 Apr; 104(4):473-80. PubMed ID: 23298313
[TBL] [Abstract][Full Text] [Related]
4. Analyses of multiple factors for determination of "selected patients" who should receive rechallenge treatment in metastatic colorectal cancer: a retrospective study from Turkey.
Ozaslan E; Duran AO; Bozkurt O; Inanc M; Ucar M; Berk V; Karaca H; Elmali F; Ozkan M
Asian Pac J Cancer Prev; 2015; 16(7):2833-8. PubMed ID: 25854370
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer.
Yang Q; Yin C; Liao F; Huang Y; He W; Jiang C; Guo G; Zhang B; Xia L
Onco Targets Ther; 2015; 8():2407-13. PubMed ID: 26366095
[TBL] [Abstract][Full Text] [Related]
6. REOX: Evaluation of the Efficacy of Retreatment With an Oxaliplatin-containing Regimen in Metastatic Colorectal Cancer: A Retrospective Single-center Study.
Costa T; Nuñez J; Felismino T; Boente L; Mello C
Clin Colorectal Cancer; 2017 Dec; 16(4):316-323. PubMed ID: 28392022
[TBL] [Abstract][Full Text] [Related]
7. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
[TBL] [Abstract][Full Text] [Related]
8. Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry.
Chong LC; Hardingham JE; Townsend AR; Piantadosi C; Rico GT; Karapetis C; Padbury R; Maddern G; Roy A; Price TJ
Target Oncol; 2020 Dec; 15(6):751-757. PubMed ID: 33068283
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer - Results from a prospective cohort study.
Marschner N; Arnold D; Engel E; Hutzschenreuter U; Rauh J; Freier W; Hartmann H; Frank M; Jänicke M
Clin Epidemiol; 2015; 7():295-303. PubMed ID: 25945067
[TBL] [Abstract][Full Text] [Related]
10. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
[TBL] [Abstract][Full Text] [Related]
11. Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients.
Fernandes GDS; Braghiroli MI; Artioli M; Paterlini ACCR; Teixeira MC; Gumz BP; Girardi DDM; Braghiroli OFM; Costa FP; Hoff PM
J Gastrointest Cancer; 2018 Dec; 49(4):470-475. PubMed ID: 28884286
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of anti-EGFR monoclonal antibodies combined with different chemotherapy regimens in patients with RAS wild-type metastatic colorectal cancer: A meta-analysis.
Sun H; Li Y; Su Y; Wu X; Zhou X; Han J; Li J
J Evid Based Med; 2019 Nov; 12(4):300-312. PubMed ID: 31596544
[TBL] [Abstract][Full Text] [Related]
13. Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
Sakai D; Taniguchi H; Sugimoto N; Tamura T; Nishina T; Hara H; Esaki T; Denda T; Sakamoto T; Okuda H; Satoh T; Tsushima T; Makiyama A; Tsuda T; Hosokawa A; Kuramochi H; Tokunaga S; Moriwaki T; Yasui H; Ishida H; Tsuji A; Otsu S; Shimokawa H; Baba E; Sato M; Matsumoto S; Ozaki Y; Shinozaki K; Tamagawa H; Goto M; Kadowaki S; Fujii H; Koh Y; Yamazaki K; Hironaka S; Kishimoto J; Boku N; Hyodo I; Muro K
Eur J Cancer; 2020 Aug; 135():11-21. PubMed ID: 32526634
[TBL] [Abstract][Full Text] [Related]
14. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
15. Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody.
Wen F; Tang R; Sang Y; Li M; Hu Q; Du Z; Zhou Y; Zhang P; He X; Li Q
Cancer Sci; 2013 Oct; 104(10):1330-8. PubMed ID: 23822592
[TBL] [Abstract][Full Text] [Related]
16. Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer.
Taşçı EŞ; Oyan B; Sönmez Ö; Mutlu AU; Atcı MM; Sakin A; Öner İ; Çınkır HY; Eryılmaz MK; Çağlayan D; Balçık OY; Paksoy N; Karabulut S; Salim DK; Bilir C; Özen M; Özçelik M; Arıcan A; Akagündüz B; İnal A; Aydın D; Özer L; Gülmez A; Turhal NS; Esen SA; Algın E; Akbaş S; İriağaç Y; Şakalar T; Ünal Ç; Er Ö; Seçmeler Ş; Bozkurt M
BMC Cancer; 2024 Jan; 24(1):16. PubMed ID: 38166764
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin rechallenge in metastatic colorectal cancer patients after prior oxaliplatin treatment.
Kim JJ; Kang J; Hong YS; Kim KP; Kim SY; Kim TW; Kim JE
Med Oncol; 2018 Apr; 35(5):65. PubMed ID: 29623500
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M
Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
Scheithauer W; Kornek GV; Brugger S; Ullrich-Pur H; Valencak J; Raderer M; Fiebiger W; Kovats E; Lang F; Depisch D
Cancer Invest; 2002; 20(1):60-8. PubMed ID: 11853004
[TBL] [Abstract][Full Text] [Related]
20. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
